{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:18:27Z","timestamp":1775218707439,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijrobp.2021.02.027","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T16:15:06Z","timestamp":1614096906000},"page":"1416-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study"],"prefix":"10.1016","volume":"110","author":[{"given":"Irving","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn J.","family":"Bubley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupal S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanna","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.02.027_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10 Year data from the ATRAAOG 96.01 randomized trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1464-410X.2010.09679.x","article-title":"A natural history of weight change in men with prostate cancer on ADT: Results from the shared equal access regional hospital (SEARCH) database","volume":"107","author":"Kim","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib5","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen deprivation therapy for prostate cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","article-title":"Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy","volume":"74","author":"Hamilton","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.juro.2017.08.103","article-title":"Long-term activity and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 3 Year open label follow up results","volume":"199","author":"Tombal","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 1 and 2 year open-label follow up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib10","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.2003.01.075","article-title":"Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era","volume":"21","author":"D\u2019Amico","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.juro.2012.01.073","article-title":"Post treatment PSA nadir predicts prostate cancer specific and all cause mortality","volume":"187","author":"Tseng","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1470-2045(11)70295-9","article-title":"Surrogate endpoints for prostate cancer mortality after radiotherapy and androgen suppression therapy in men with localized or locally advanced prostate cancer: An analysis of two randomized trials","volume":"13","author":"D\u2019Amico","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13014-017-0884-y","article-title":"Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation","volume":"12","author":"Geara","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2016.5983","article-title":"Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy versus radiation therapy plus androgen deprivation therapy","volume":"3","author":"Royce","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib18","doi-asserted-by":"crossref","first-page":"t119","DOI":"10.1530\/ERC-13-0467","article-title":"Androgen deprivation therapy complications","volume":"21","author":"Allan","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","article-title":"The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis","volume":"4","author":"Haseen","year":"2010","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685530500361226","article-title":"The effect of 6 months of androgen deprivation on muscle and fat mass in older men with localized prostate cancer","volume":"8","author":"Boxer","year":"2005","journal-title":"Aging Male"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-18-0117","article-title":"Persistent adverse body composition changes 2 years after cessation of androgen deprivation therapy for localized prostate cancer","volume":"179","author":"Cheung","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ijrobp.2021.02.027_bib23","first-page":"1555","article-title":"PSA course after definitive high-dose radiotherapy of localized prostate cancer","volume":"3A","author":"Schuller","year":"2005","journal-title":"Anticancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:53:54Z","timestamp":1759744434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621002054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0360301621002054"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.027","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}